UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Enrolling by invitation
Unique ID issued by UMIN UMIN000023890
Receipt No. R000025803
Scientific Title Posttransplantation cyclophosphamide and tacrolimus for prevention of Graft-versus-host disease in allogeneic hematopoietic stem cell transplantation from HLA matched sibling or unrelated donor: a single center prospective phase II study (OCU16-1)
Date of disclosure of the study information 2016/09/01
Last modified on 2016/09/01

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Posttransplantation cyclophosphamide and tacrolimus for prevention of Graft-versus-host disease in allogeneic hematopoietic stem cell transplantation from HLA matched sibling or unrelated donor: a single center prospective phase II study (OCU16-1)
Acronym PTCy and tacrolimus for GVHD prevention after allo-HCT from HLA matched donor (OCU16-1)
Scientific Title Posttransplantation cyclophosphamide and tacrolimus for prevention of Graft-versus-host disease in allogeneic hematopoietic stem cell transplantation from HLA matched sibling or unrelated donor: a single center prospective phase II study (OCU16-1)
Scientific Title:Acronym PTCy and tacrolimus for GVHD prevention after allo-HCT from HLA matched donor (OCU16-1)
Region
Japan

Condition
Condition Acute myeloid leukemia(AML)
Acute lymphoblastic leukemia(ALL)
Acute leukemias of ambiguous lineage
Myelodysplastic syndrome(MDS)
Chronic myeloid leukemia(CML)
Malignant lymphoma(ML)
Classification by specialty
Hematology and clinical oncology
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 Evaluation for safety and efficacy of PTCy and Tac for GVHD prevention of allo-HCT from HLA matched donor in Japan.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes 1 year chronic GVHD free survival
Key secondary outcomes

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Cy is intravenously administered at 50mg/kg/day on days 3 and 4. Continuous intravenous infusion of Tac is started at 0.03mg/kg/day from day 5. Unless GVHD developed, Tac was tapered from day 60-100 and stopped until day 180.
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
15 years-old <=
Age-upper limit
70 years-old >
Gender Male and Female
Key inclusion criteria (1) Disease
(a) AML
(b) ALL
(c) Acute leukemias of ambiguous lineage
(d) MDS
1. IPSS int-2 or high
2. Transfusion dependent MDS (more than 2 unit RBC or 10 unit platelet weekly transfusion)
(e) CML
1. CP beyond 1st CP
2. TKI failure in 1st CP
(f) malignant lymphoma
1. Indolent lymphoma after 1st relapse/progression
2. Aggressive lymphoma
*Chemo-refractory lymphoma after 1st relapse, or
*Lymphoma after 2nd relapse, or
*relapsed Lymphoma after auto-HCT
(g) a rare hematological malignancy except for (a)~(f) that was judged as necessity of allo-HCT in our conference

(2) Age >=15 and < 70 years old
(3) ECOG PS 0 or 1
(4) Normal function of major organs
(5) donor: presence of available sibling or unrelated donor with HLA-A, B, C, and DRB1 allele 8/8 match in GVH direction
(Note: no limitation for conditioning regimen intensity)
Key exclusion criteria 1) Major organ dysfunction
a) Total bilirubin:>= 2.0mg/dl
b) Serum creatinine: >= 2.0mg/dl
c) Ejection fraction: < 50 %
d) Pulmonary function test: %VC <40%, FEV1.0% <50% or SaO2 <90% on room air
e) AST or ALT >= 3 x UNL
2) Uncontrolled active infection
3) Uncontrolled CNS invasion
4) Poorly controlled insulin-treated
diabetes mellitus
5) Poorly controlled hypertension
6) Patients with a severe complication including heart failure, liver failure, acute myocardial infarction within the last three months, liver cirrhosis and interstitial pneumonia
7) Pregnant, lactating or possible fertile women who may become pregnant
8) Patients with a severe mental who are likely to be unable to participate in the study

9) A history of hypersensitivity or allergy to any drugs in the conditioning regimen of this transplant
10) HIV antibody positivity
11) The administration of ATG is scheduled in conditioning regimen.
12) The physician in charge determines that there is no indication to perform this intervention.
(Note: HBs antigen positivity and HCV antibody positivity is not exclusion criterion.)
Target sample size 39

Research contact person
Last name of lead principal investigator
1st name
Middle name
Last name Takahiko Nakane
Organization Osaka City University, Graduate School of Medicine
Division name Hematology
Zip code
Address 1-4-3, Asahi-machi, Abeno-ku, Osaka, Japan, 545-8585
TEL 06-6645-3881
Email nakane@med.osaka-cu.ac.jp

Public contact
1st name of contact person
1st name
Middle name
Last name Takahiko Nakane
Organization Osaka City University, Graduate School of Medicine
Division name Hematology
Zip code
Address 1-4-3, Asahi-machi, Abeno-ku, Osaka, Japan, 545-8585
TEL 06-6645-3881
Homepage URL
Email nakane@med.osaka-cu.ac.jp

Sponsor
Institute Osaka City University
Institute
Department

Funding Source
Organization None
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2016 Year 09 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Enrolling by invitation
Date of protocol fixation
2016 Year 07 Month 01 Day
Date of IRB
Anticipated trial start date
2016 Year 10 Month 14 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2016 Year 09 Month 01 Day
Last modified on
2016 Year 09 Month 01 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025803

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.